SLC12A5 and glioma: Blockade of excess glutamate release from glioma cells with SAS prevents KCC2 downregulation in GBM cells (MacKenzie et al., 2016), implicating increased glutamate signaling in Cl− gradient dysregulation and aberrant GABAergic neurotransmission.